Bausch + Lomb Corporation (BLCO)

Eye care plants and sales force, counted. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 18, 2026. Ranked 48 of the 95 Healthcare companies read so far, by the share within reach now.

The filing counts 13,000 employees by function, 7,000 in production and 4,200 in sales, 38% in the United States, making contact lenses, eye health products and pharmaceuticals.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 34% at the end of 2027, 40% at the end of 2028, 43% at the end of 2030. By the patterns, the work is about 43% desk work, 15% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 55% of the working time stays with people (conversation, in-person and hands-on work), 37% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

13,000 employees as of December 31, 2025 (stated). Approximately 4,900 of 13,000 employees in the United States (38%), 3,400 in Europe excluding Ireland, 2,200 in Asia-Pacific, 1,500 in Ireland, stated.

The filing: “As of December 31, 2025, we had approximately 13,000 employees, which included approximately 7,000 in production, 4,200 in sales and marketing, 900 in general and administrative positions and 900 in R&D.”

The workforce as industry patterns

What the filing says about the workforce: 7,000 production, 4,200 sales and marketing, 900 general and administrative, 900 R&D; 4,900 U.S., 3,400 Europe, 2,200 Asia-Pacific, 1,500 Ireland, 400 Latin America, 400 Russia and CIS, 100 Canada, 100 Middle East and Africa; collective bargaining for some employees in several countries; days away rate 5.5.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

39 sentences in the filing name AI. Thirty-nine sentences: the company launched an AI Academy for employees in 2025 and names state and federal AI laws among its regulatory risks.

• “Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations; the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the "Health Care Reform Act") and any p...”
• “Such adequacy decision was extended until December 2031, however, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs, it could lead to additional costs and increase our overall risk exposure. 10 Several laws have been enacted at the U.S. state level that regulate the development and deployment of artificial intelligence ("AI") platforms and sy...”
• “Although there are no U.S. federal laws specifically governing AI development and use, federal agencies in the United States are applying existing laws to address AI-related risks.”
• “An Executive Order issued in December 2025 seeks to establish uniform federal standards and challenge state laws that regulate AI.”
• “As with data privacy laws, these state laws and possible federal regulation could have significant effects on our Company and require us to change our AI practices and incur substantial costs and expenses in order to comply.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20220median 0
• Fiscal 20230median 1
• Fiscal 202414median 4
• Fiscal 202539median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The split of production and sales between the pharmaceutical and device patterns is by description and revenue mix (c); the function counts are stated.
• The general and administrative count (900) is read at management of companies under rule 6.

Source: the company's annual report on EDGAR, accession 0001860742-26-000007, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.